mRNA-4394
Phase 1RNA therapy
ModernamRNA-4394 is one of 47 therapeutic programs targeting Prostate Carcinoma. It is currently in Phase 1.
1
Indications
0
Total Trials
0
Active Trials
46
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
56 competitors in Prostate Carcinoma
#DrugCompanyPhaseTrials
1Erleada
Johnson & JohnsonApproved
Nubeqa
BayerApproved
Lupron
AbbVieApproved
Zometa
PfizerApproved
Jevtana
SanofiApproved
Plaquenil
Alnylam PharmaceuticalsApproved
Ritalin
NovartisApproved
Lynparza
AstraZenecaApproved
Balversa
Johnson & JohnsonApproved
Estrace
Novo NordiskApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for mRNA-4394. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Modality
- RNA therapy
- Highest Phase
- Phase 1
- Company